Estimating the incidence of breast cancer recurrence using administrative data.
Administrative data
Breast cancer
Distant
Local
Locoregional
Metastasis
Recurrence
Regional
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
20
09
2022
accepted:
09
11
2022
pubmed:
25
11
2022
medline:
28
3
2023
entrez:
24
11
2022
Statut:
ppublish
Résumé
Breast cancer is the most common cancer among women, but most cancer registries do not capture recurrences. We estimated the incidence of local, regional, and distant recurrences using administrative data. Patients diagnosed with stage I-III primary breast cancer in Ontario, Canada from 2013 to 2017 were included. Patients were followed until 31/Dec/2021, death, or a new primary cancer diagnosis. We used hospital administrative data (diagnostic and intervention codes) to identify local recurrence, regional recurrence, and distant metastasis after primary diagnosis. We used logistic regression to explore factors associated with developing a distant metastasis. With a median follow-up 67 months, 5,431/45,857 (11.8%) of patients developed a distant metastasis a median 23 (9, 42) months after diagnosis of the primary tumor. 1086 (2.4%) and 1069 (2.3%) patients developed an isolated regional or a local recurrence, respectively. Patients with distant metastatic disease had a median overall survival of 15.4 months (95% CI 14.4-16.4 months) from the time recurrence/metastasis was identified. In contrast, the median survival for all other patients was not reached. Patients were more likely to develop a distant metastasis if they had more advanced stage, greater comorbidity, and presented with symptoms (p < 0.0001). Trastuzumab halved the risk of recurrence [OR 0.53 (0.45-0.63), p < 0.0001]. Distant metastasis is not a rare outcome for patients diagnosed with breast cancer, translating to an annual incidence of 2132 new cases (17.8% of all breast cancer diagnoses). Overall survival remains high for patients with locoregional recurrences, but was poor following a diagnosis of a distant metastasis.
Sections du résumé
BACKGROUND
BACKGROUND
Breast cancer is the most common cancer among women, but most cancer registries do not capture recurrences. We estimated the incidence of local, regional, and distant recurrences using administrative data.
METHODS
METHODS
Patients diagnosed with stage I-III primary breast cancer in Ontario, Canada from 2013 to 2017 were included. Patients were followed until 31/Dec/2021, death, or a new primary cancer diagnosis. We used hospital administrative data (diagnostic and intervention codes) to identify local recurrence, regional recurrence, and distant metastasis after primary diagnosis. We used logistic regression to explore factors associated with developing a distant metastasis.
RESULTS
RESULTS
With a median follow-up 67 months, 5,431/45,857 (11.8%) of patients developed a distant metastasis a median 23 (9, 42) months after diagnosis of the primary tumor. 1086 (2.4%) and 1069 (2.3%) patients developed an isolated regional or a local recurrence, respectively. Patients with distant metastatic disease had a median overall survival of 15.4 months (95% CI 14.4-16.4 months) from the time recurrence/metastasis was identified. In contrast, the median survival for all other patients was not reached. Patients were more likely to develop a distant metastasis if they had more advanced stage, greater comorbidity, and presented with symptoms (p < 0.0001). Trastuzumab halved the risk of recurrence [OR 0.53 (0.45-0.63), p < 0.0001].
CONCLUSION
CONCLUSIONS
Distant metastasis is not a rare outcome for patients diagnosed with breast cancer, translating to an annual incidence of 2132 new cases (17.8% of all breast cancer diagnoses). Overall survival remains high for patients with locoregional recurrences, but was poor following a diagnosis of a distant metastasis.
Identifiants
pubmed: 36422755
doi: 10.1007/s10549-022-06812-z
pii: 10.1007/s10549-022-06812-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
509-522Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Warren J, Yabroff K (2015) Challenges and opportunities in measuring cancer recurrence in the United States: PubMed: NCBI. J Natl Cancer Inst 107:8
doi: 10.1093/jnci/djv134
Vuksanovic D, Sanmugarajah J, Lunn D, Sawhney R, Eu K, Liang R (2021) Unmet needs in breast cancer survivors are common, and multidisciplinary care is underutilised: the Survivorship Needs Assessment Project. Breast Cancer 28(2):289–297
Koch L, Bertram H, Eberle A et al (2014) Fear of recurrence in long-term breast cancer survivors: still an issue. Results on prevalence, determinants, and the association with quality of life and depression from the cancer survivorship: a multi-regional population-based study. Psychooncology 23(5):547–554
doi: 10.1002/pon.3452
pubmed: 24293081
Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M (2017) Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev 26(6):809–815
doi: 10.1158/1055-9965.EPI-16-0889
pubmed: 28522448
pmcid: 5833304
Muradali D, Kennedy EB, Eisen A, Holloway CMB, Smith CR, Chiarelli AM (2017) Breast screening for survivors of breast cancer: a systematic review. Prev Med (Baltim) 103:70–75
doi: 10.1016/j.ypmed.2017.07.026
Darby S, McGale P, Correa C et al (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet 378(9804):1707–1716
doi: 10.1016/S0140-6736(11)61629-2
pubmed: 22019144
Dong Y, Zhang WW, Wang J, Sun JY, He ZY, Wu SG (2019) The 21-gene recurrence score and effects of adjuvant radiotherapy after breast conserving surgery in early-stage breast cancer. Futur Oncol 15(14):1629–1639
doi: 10.2217/fon-2018-0967
Bradley R, Burrett J, Clarke M et al (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386(10001):1341–1352
doi: 10.1016/S0140-6736(15)61074-1
Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15):4429–4434
doi: 10.1158/1078-0432.CCR-06-3045
pubmed: 17671126
Siotos C, Naska A, Bello RJ et al (2019) Survival and disease recurrence rates among breast cancer patients following mastectomy with or without breast reconstruction. Plast Reconstr Surg 144(2):169e–177e
doi: 10.1097/PRS.0000000000005798
pubmed: 31348330
Voogd AC, Nielsen M, Peterse JL et al (2001) Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 19(6):1688–1697
doi: 10.1200/JCO.2001.19.6.1688
pubmed: 11250998
Chubak J, Yu O, Pocobelli G et al (2012) Administrative data algorithms to identify second breast cancer events following early-stage invasive breast cancer. J Natl Cancer Inst 104(12):931–940
doi: 10.1093/jnci/djs233
pubmed: 22547340
pmcid: 3732250
Xu Y, Kong S, Cheung WY et al (2019) Development and validation of case-finding algorithms for recurrence of breast cancer using routinely collected administrative data. BMC Cancer 19:1
doi: 10.1186/s12885-019-5432-8
Ritzwoller DP, Hassett MJ, Uno H et al (2018) Development, validation, and dissemination of a breast cancer recurrence detection and timing informatics algorithm. J Natl Cancer Inst 110(3):273–281
doi: 10.1093/jnci/djx200
pubmed: 29873757
Mariotto AB, Zou Z, Zhang F, Howlader N, Kurian AW, Etzioni R (2018) Can we use survival data from cancer registries to learn about disease recurrence? The case of breast cancer. Cancer Epidemiol Biomarkers Prev 27(11):1332–1341
doi: 10.1158/1055-9965.EPI-17-1129
pubmed: 30337342
pmcid: 8343992
Haque R, Shi J, Schottinger JE et al (2015) A hybrid approach to identify subsequent breast cancer using pathology and automated health information data. Med Care 53(4):380–385
doi: 10.1097/MLR.0000000000000327
pubmed: 25769058
Habbous S, Homenauth E, Barisic A et al (2022) Differences in breast cancer diagnosis by patient presentation in Ontario: a retrospective cohort study. C Open 10(2):E313–E330
doi: 10.9778/cmajo.20210254
pubmed: 35383035
pmcid: 9259434
Padmanabhan N, Subramanyan A, Radhakrishna S (2015) Synchronous bilateral breast cancers. J Clin Diagnostic Res 9(9):10–13
Botteri E, Bagnardi V, Rotmensz N et al (2009) Analysis of local regional recurrences in breast cancer after conservative surgery. Ann Oncol 21(4):723–728
doi: 10.1093/annonc/mdp386
pubmed: 19833817
Luo C, Zhong X, Deng L, Xie Y, Hu K, Zheng H (2019) Nomogram predicting locoregional recurrence to assist decision-making of postmastectomy radiation therapy in patients with T1–2N1 breast cancer. Int J Radiat Oncol Biol Phys 103(4):905–912
doi: 10.1016/j.ijrobp.2018.11.005
pubmed: 30419307
Tovar JR, Zandonade E, Amorim MHC (2014) Factors associated with the incidence of local recurrences of breast cancer in women who underwent conservative surgery. Int J Breast Cancer 2014:639534
Spronk I, Schellevis FG, Burgers JS, de Bock GH, Korevaar JC (2018) Incidence of isolated local breast cancer recurrence and contralateral breast cancer: a systematic review. Breast 39:70–79
doi: 10.1016/j.breast.2018.03.011
pubmed: 29621695
Geurts YM, Witteveen A, Bretveld R et al (2017) Patterns and predictors of first and subsequent recurrence in women with early breast cancer. Breast Cancer Res Treat 165(3):709–720
doi: 10.1007/s10549-017-4340-3
pubmed: 28677011
pmcid: 5602040
Hassett MJ, Ritzwoller DP, Taback N et al (2014) Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using two large contemporary cohorts. Med Care 52(10):e65–e73
doi: 10.1097/MLR.0b013e318277eb6f
pubmed: 23222531
pmcid: 3600389
Warren JL, Mariotto A, Melbert D et al (2016) Sensitivity of Medicare claims to identify cancer recurrence in elderly colorectal and breast cancer patients. Med Care 54(8):e47–e54
doi: 10.1097/MLR.0000000000000058
pubmed: 24374419
pmcid: 4072852
Wapnir IL, Khan A (2019) Current strategies for the management of locoregional breast cancer recurrence. Oncol (United States) 33(1):19–25
Rasmussen LA, Jensen H, Virgilsen LF, Thorsen LBJ, Offersen BV, Vedsted P (2019) A validated algorithm for register-based identification of patients with recurrence of breast cancer—based on danish breast cancer group (DBCG) data. Cancer Epidemiol 59:129–134
doi: 10.1016/j.canep.2019.01.016
Holloway CMB, Shabestari O, Eberg M et al (2022) Identifying breast cancer recurrence in administrative data: algorithm development and validation. Curr Oncol 29(8):5338–5367
doi: 10.3390/curroncol29080424
pubmed: 36005162
pmcid: 9406366
Kroenke CH, Chubak J, Johnson L, Castillo A, Weltzien E, Caan BJ (2016) Enhancing breast cancer recurrence algorithms through selective use of medical record data. JNCI J Natl Cancer Inst 108(3):336
doi: 10.1093/jnci/djv336
Habbous S, Forster K, Darling G et al (2020) Incidence and real-world burden of brain metastases from solid tumors and hematologic malignancies in Ontario: a population-based study. Neuro-oncology Adv 3:1
Ontario Cancer Statistics 2020. 2020. https://www.cancercareontario.ca/en/statistical-reports/ontario-cancer-statistics-2020/ch-1-estimated-current-cancer-incidence . Accessed November 11, 2020
Pagani O, Senkus E, Wood W et al (2010) International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? JNCI J Natl Cancer Inst 102(7):456
doi: 10.1093/jnci/djq029
pubmed: 20220104
Coleman M, Forman D, Bryant H et al (2011) Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 377(9760):127–138
doi: 10.1016/S0140-6736(10)62231-3
pubmed: 21183212
pmcid: 3018568
Miksad RA, Zietemann V, Gothe R et al (2008) Progression-free survival as a surrogate endpoint in advanced breast cancer. Int J Technol Assess Health Care 24(4):371–383
doi: 10.1017/S0266462308080495
pubmed: 18828930
pmcid: 4744081
Kemp R, Prasad V (2017) Surrogate endpoints in oncology: When are they acceptable for regulatory and clinical decisions, and are they currently overused? BMC Med 15:1
doi: 10.1186/s12916-017-0902-9
Hernandez-Villafuerte K, Fischer A, Latimer N (2018) Challenges and methodologies in using progression free survival as a surrogate for overall survival in oncology. Int J Technol Assess Health Care 34(3):300–316
doi: 10.1017/S0266462318000338
pubmed: 29987997
Seely JM, Alhassan T (2018) Screening for breast cancer in 2018—what should we be doing today? Curr Oncol 25(Suppl 1):S115–S124
doi: 10.3747/co.25.3770
pubmed: 29910654
pmcid: 6001765
Jones T, Duquette D, Underhill M et al (2018) Surveillance for cancer recurrence in long-term young breast cancer survivors randomly selected from a statewide cancer registry. Breast Cancer Res Treat 169(1):141–152
doi: 10.1007/s10549-018-4674-5
pubmed: 29353367
Zeng Z, Espino S, Roy A et al (2018) Using natural language processing and machine learning to identify breast cancer local recurrence. BMC Bioinformatics 19(Suppl 17):498
doi: 10.1186/s12859-018-2466-x
pubmed: 30591037
pmcid: 6309052